Subgroup	Study number	Events/total	Proportion	n Proporti	on 95% CI	P
Daily dose (mg/kg)						: 0.56
More than 30	3	57/61	94.97			⊣
Less than 30	2	19/21	90.94	-		⊣
Combination of antibi	otic					0.29
Yes	2	42/44	96.20		- 	⊣ i
No	3	34/38	89.88	-	- i -	⊣ }
Combination of other	drugs				1	: 0.36
No	2	19/20	97.85			H.
Yes	3	57/62	92.44	-		⊣ :
					0.9268	1.00
Total	5	76/82	92.68	0.75 0.85		1.00

Supplementary Fig. 1 Subgroup meta-analysis of microbial eradication in children after linezolid therapy. *CI* confidence interval

Subgroup	Study number	Events/total	Proportion	Proportion 95% CI	P
Pathogen	1.70				0.54
Gram positive	3	2/54	2.64	<u> </u>	
Suspected Gram positiv		13/704	0.86	—	
Daily dose (mg/kg)		10,,0	0.00	<u> </u>	0.16
More than 30	5	15/388	2.46	—	
Less than 30	4	0/370	0.00	•	
Administration of linezo		0,5,0	0.00	Ī	0.24
Orally ^a	6	15/599	1.75	——	
Intravenously	3	0/159	0.00	<u> </u>	
Adjustment of dosage	2	0/157	0.00	7	0.27
No	7	15/632	1.46	<u> </u>	0.27
Yes	2	0/126	0.00	<u>. </u>	
Duration of treatment (d		0/120	0.00	7	0.47
Less than 14	6	13/707	0.84	<u></u>	0.17
More than 14	3	2/51	3.13	<u> </u>	_
Combination of antibioti		2/31	5.15	-	0.74
Yes	3	2/54	2.64	<u> </u>	0.71
No	4	13/550	1.56		
Combination of other dr		13/330	1.50	- '	0.19
No	3	0/100	0.00	<u> </u>	0.17
Yes	4	15/504	2.86		
Race	-	13/304	2.00	- ·	0.50
White	5	13/595	1.17	<u>. </u>	0.50
Other	4	2/163	0.20		
Sample size	-	2/103	0.20	<u> </u>	0.70
Less than 30 patients	3	0/36	0.00	<u> </u>	0.70
More than 30 patients	6	15/722	1.17	 -	
Concentration monitoring	CH190 H19001	13/122	1.17	-	0.17
No	or infezona 4	15/507	2.76	<u> </u>	0.17
Yes	5	0/251	0.00	<u> </u>	
105	3	0/231	0.00	_	
Total	9	15/758	0.16	0.00 0.05	0.10

Supplementary Fig. 2 Subgroup analysis of all-cause mortality in children after linezolid therapy. *CI* confidence interval. ^aIncluding patients receiving sequential therapy of linezolid